Related Experiment Videos
Pattern visual evoked potential mapping in Alzheimer's disease: correlations with visuospatial impairment
V Martinelli1, T Locatelli, G Comi
1Department of Neurology, University of Milan, Italy.
Summary
Alzheimer's disease (AD) patients show delayed visual evoked potentials (PVEPs) in later components, specifically N140 and P200. These delays correlate with visuospatial impairments, suggesting specific visual pathway dysfunction.
Area of Science:
- Neuroscience
- Ophthalmology
- Neurology
Background:
- Alzheimer's disease (AD) is a neurodegenerative disorder impacting cognition and often causing visual disturbances.
- Understanding the neurophysiological basis of visual impairments in AD is crucial for diagnosis and management.
Purpose of the Study:
- To evaluate pattern visual evoked potentials (PVEPs) in AD patients.
- To correlate PVEP findings with visuospatial performance.
- To elucidate the causes of visual disturbances in Alzheimer's disease.
Main Methods:
- Assessed PVEPs in 20 AD patients and compared with healthy controls.
- Administered a comprehensive neuropsychological test battery, focusing on visuospatial abilities.
- Analyzed latencies and topographical distribution of PVEP components (N70, P100, N140, P200).
Main Results:
- AD patients exhibited normal latencies for N70 and P100 PVEP components.
- Significantly increased latencies were observed for N140 and P200 in AD patients compared to controls.
- No significant differences in the topographical distribution of PVEP components were found between groups.
- 40% of AD patients showed visuospatial impairment.
- A positive correlation existed between P200 amplitude (right posterior hemisphere) and visuospatial test performance.
Conclusions:
- Findings suggest sparing of foveal retinocortical pathways in AD.
- Evidence points to selective dysfunction in corticocortical connections or right temporo-parieto-occipital visual analyzers.
- PVEP abnormalities, particularly delayed N140 and P200, are associated with visuospatial deficits in Alzheimer's disease.